

Clearbridge Completes the Acquisition of a Majority Stake in 9 Dental Clinics in Singapore

- *Clearbridge now owns a 51% effective interest in 9 dental clinics under the “Dental Focus” brand name with the first right of refusal to acquire another 6 dental clinics and ancillary dental services providers*
- *Strengthens Clearbridge’s precision medicine platform in Asia with a larger primary healthcare network through this dentistry business*
- *Strong potential to replicate dentistry specialisation and operational know-how across Clearbridge’s regional healthcare presence for further value creation*
- *Acquisition expected to have a positive impact on the Group’s financial performance for the financial year ending 31 December 2019*

SINGAPORE, 29 August 2019 – Integrated healthcare company, **Clearbridge Health Limited** (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (“明策集团”), is pleased to announce that it has completed the acquisition of a majority stake in 9 dental clinics in Singapore, operating under the brand name “Dental Focus”. The acquisition was announced on 24 May 2019.

With the first “Dental Focus” dental clinic set up in 2011, it has expanded into a network of dental clinics across Singapore, offering a wide range of dental services that includes primary dental care, restorative and aesthetics dentistry and pain management.

These 9 dental clinics will continue to be led by Dr Joseph Seow Kok Siam, who has more than 35 years of dentistry experience in Singapore, and will continue to practice as a dental surgeon in one of the dental clinics.

Notably, Dr Seow has significant experience and a proven track record in building chains of successful dental clinics in his past working experiences in other listed healthcare companies. In addition, Dr Seow is actively involved in the training of dentists and staff in the “Dental Focus” network to ensure high service standards and best-in-class patient care.

The 9 dental clinics collectively generated approximately S\$6.3 million of revenue in the last financial year and are profitable. The acquisition is expected to have a positive impact on the Group’s financial performance for the financial year ending 31 December 2019.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said, “Uniting our specialised knowledge and operational know-how in the healthcare industry, we will be looking to expand our dentistry business across our regional platform to develop new patient base and create a larger primary healthcare network.”



Precision medicine involves a personalised approach to healthcare and with a larger base of patients, this acquisition will also facilitate greater access for Clearbridge to target more patients and accelerate the adoption of precision medicine, specific to individuals in a way that improve and sustains health.”

– END –

Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

About Clearbridge Health Limited

(Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3)

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises healthcare systems, medical clinics/centres and strategic equity investments in medical technology companies.

Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. It is executing the above strategies by way of primary healthcare and healthcare systems that reside in nexus of high demand.

For more information, please visit us at www.clearbridgehealth.com.

This press release has been prepared by the Company and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalyst. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.